SecBot SecBot
8-K ·Filed Aug 10, 2026

ENTA

ENANTA PHARMACEUTICALS INC
BULLISH
Impact 7/10
Horizondays Processed3mo ago SEC0001193125-26-342336
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

Enanta reported a narrower-than-expected net loss of $0.45 per share for fiscal Q2 2026, beating the consensus estimate of -$0.51 by 11.8%, while revenue of $17.2M exceeded the $16.8M consensus, driven by higher AbbVie royalty revenue; the company also initiated dosing in a Phase 1 trial of EDP-978 and advanced its RSV pipeline toward a registrational trial, reinforcing its clinical-stage catalyst trajectory.

DirectionBullish
Horizondays

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.52
T+0 close · Aug 10, 2026 · via day close
Latest settled
−21.23%
T+60 · $10.65
Vs SPY
−20.74%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $13.52entry
  2. T+1 · 3mo ago −0.15%α −0.40% · $13.50
  3. T+5 · 3mo ago −1.63%α −1.22% · $13.30
  4. T+20 · 2mo ago −2.07%α −1.01% · $13.24
  5. T+60 · 13d ago −21.23%α −20.74% · $10.65
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Enanta reported a narrower-than-expected net loss of $0.45 per share for fiscal Q2 2026, beating the consensus estimate of -$0.51 by 11.8%, while revenue of $17.2M exceeded the $16.8M consensus, driven by higher AbbVie royalty revenue; the company also initiated dosing in a Phase 1 trial of EDP-978 and advanced its RSV pipeline toward a registrational trial, reinforcing its clinical-stage catalyst trajectory.

Financial Impact

Not specified

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-342336
Document: enta-20260810.htm0001193125-26-342336
Document: 0001193125-26-342336-index-headers.html0001193125-26-342336
Document: 0001193125-26-342336-index.html0001193125-26-342336
Document: 0001193125-26-342336.txt0001193125-26-342336
8-K Data (Synthetic)0001193125-26-342336

Track record

7 reports on ENTA

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $11.20 Now $10.67 −4.73% settles Nov 24
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $10.99 Now $10.67 +2.91% settles Nov 23
  3. Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $11.22 Now $10.67 −4.90% settles Nov 17
  4. Oct 29, 202618d ago 8-K Bearish 7/10 Entry $10.71 to $11.00 Now $10.67 +0.37% ▼ −2.71% −5.41% vs SPY
  5. Oct 28, 202619d ago 8-K Neutral 3/10 Entry $11.55 to $10.65 Now $10.67 −7.62% ▼ −7.79% −7.08% vs SPY
  6. Oct 27, 202620d ago SC 13G Neutral 4/10 Entry $11.55 to $10.65 Now $10.67 −7.62% ▼ −7.79% −7.08% vs SPY
  7. Aug 10, 202614w ago 8-K Bullish 7/10 Viewing Entry $13.52 to $13.30 Now $10.67 −21.08% ▼ −1.63% −1.22% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens in 6h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026